Nektar Therapeutics (NKTR)
1.225
-0.10
(-7.20%)
USD |
NASDAQ |
Apr 19, 14:56
Nektar Therapeutics Enterprise Value: -61.24M for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | -61.24M |
| April 17, 2024 | -55.73M |
| April 16, 2024 | -30.03M |
| April 15, 2024 | -15.34M |
| April 12, 2024 | 3.026M |
| April 11, 2024 | -13.50M |
| April 10, 2024 | -66.75M |
| April 09, 2024 | -74.09M |
| April 08, 2024 | -63.08M |
| April 05, 2024 | -61.24M |
| April 04, 2024 | -61.24M |
| April 03, 2024 | -112.65M |
| April 02, 2024 | -129.18M |
| April 01, 2024 | -137.61M |
| March 28, 2024 | -132.08M |
| March 27, 2024 | -141.10M |
| March 26, 2024 | -138.36M |
| March 25, 2024 | -140.54M |
| March 22, 2024 | -135.88M |
| March 21, 2024 | -138.86M |
| March 20, 2024 | -138.36M |
| March 19, 2024 | -144.20M |
| March 18, 2024 | -147.54M |
| March 15, 2024 | -145.67M |
| March 14, 2024 | -145.70M |
| Date | Value |
|---|---|
| March 13, 2024 | -147.54M |
| March 12, 2024 | -140.20M |
| March 11, 2024 | -150.90M |
| March 08, 2024 | -136.69M |
| March 07, 2024 | -128.15M |
| March 06, 2024 | -136.54M |
| March 05, 2024 | -141.28M |
| March 04, 2024 | -138.36M |
| March 01, 2024 | -160.39M |
| February 29, 2024 | -173.25M |
| February 28, 2024 | -171.41M |
| February 27, 2024 | -165.90M |
| February 26, 2024 | -175.39M |
| February 23, 2024 | -173.02M |
| February 22, 2024 | -177.11M |
| February 21, 2024 | -171.56M |
| February 20, 2024 | -176.61M |
| February 16, 2024 | -167.37M |
| February 15, 2024 | -161.99M |
| February 14, 2024 | -156.25M |
| February 13, 2024 | -178.26M |
| February 12, 2024 | -167.35M |
| February 09, 2024 | -167.73M |
| February 08, 2024 | -172.52M |
| February 07, 2024 | -175.39M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-384.62M
Minimum
Mar 30 2023
5.078B
Maximum
Jul 03 2019
1.393B
Average
1.707B
Median
Enterprise Value Benchmarks
| Stereotaxis Inc | 186.97M |
| Vanda Pharmaceuticals Inc | -102.30M |
| Cara Therapeutics Inc | -63.05M |
| Marinus Pharmaceuticals Inc | 0.1387M |
| DiaMedica Therapeutics Inc | 41.62M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -42.08M |
| Revenue (Quarterly) | 23.88M |
| Total Expenses (Quarterly) | 54.54M |
| EPS Diluted (Quarterly) | -0.22 |
| Gross Profit Margin (Quarterly) | 69.51% |
| Profit Margin (Quarterly) | -176.2% |
| Earnings Yield | -119.2% |
| Normalized Earnings Yield | -63.78 |